Topic

Articles

Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.

Partnerships Are Key to Niche Markets in Brazil

Looks to address disconnect between registration and reimbursement.

Europe Searches for Better Collaboration Across Regulators

 leads Simon-Kucher’s Life Sciences division in Greater China.

Duo Xu, Miranda Wang and Selene Peng are consultants with experience across diverse therapeutic areas, and recent experience on NRDL and innovative access options in China.

Tong Wang and Justinian Liu are senior consultants at Simon-Kucher’s Life Sciences division in Greater China. 

China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.

China 2021: The NRDL Readout 

Lack of IP management plagues recent regulatory discussions.

IP and Pharmaceutical Trade: Europe’s Unresolved Debate

Josh Lee is a project manager with years of experience in China pharmaceutical pricing and access strategies.

 is a senior consultant specialized in China pharma and healthcare industry.

To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.

Maximizing China Access for Innovative Therapies

Bruce Liu leads Simon-Kucher’s Life Sciences division in Greater China. He has over 20 years of experience in the life sciences industry and is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

Shiyi He is a consultant with extensive experience in health economics and payer strategies in China.

Ivy Jiang is a consultant with years of experience in China pharmaceutical pricing and access strategies.

Duo Xu is a consultant specialized in China pharma and healthcare industry with recent experience on NRDL renewals.

Selene Peng is a consultant with experience across diverse therapeutic areas, and recent experience on NRDL trends and outlook.

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.


China 2021 National Reimbursement Drug List Outlook

Committee struggles to find a common treatment approach.

EU MEPs Arrive At Crossroads in Cancer Strategy

Bruce Liu is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

MBA from the University of Chicago, MSc in molecular biology from the University of Rochester, and BSc in biochemistry from Fudan University.

Tong Wang is a Senior Consultant in Simon-Kucher's Life Sciences division and is based in the Shanghai office. He has supported a breadth of projects, working with pharmaceutical and medical technology companies in the China and US markets. His experience includes launch strategies, P&MA strategies, reimbursement strategies, and market opportunity evaluation. MSc in bioengineering from Rice University and obtained his BSc in biomedical engineering from Shanghai Jiao Tong University.

 is a Senior Consultant with experience in a breadth of projects working with both pharmaceutical and medtech companies in US, EU and China markets. His experience includes launch strategy, P&MA strategy, reimbursement strategies and P&MA tool development. Ph.D. from The University of California, Los Angeles in Molecular Biology.

 is a Senior Consultant with experience in the pharmaceutical industry and healthcare policies. Her areas of specialty include pricing strategies, market access opportunities, as well as post-launch competitive positioning in China. Master's degree in public administration with major in policy research analysis from the University of Pittsburg and a Bachelor's degree in public health administration.

Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.

Improving Readiness for Volume-Based Procurement in China

New EU initiative aims to curve shortage of vaccines and therapies.

A FAB Opportunity Emerging for Europe’s Drugmakers

OM Pharma, active in the prevention of recurrent respiratory and urinary tract infections, wins the 2021 Geneva Economy Award.

Global